Real-world effectiveness and safety of fixed-duration frontline venetoclax–obinutuzumab for chronic lymphocytic leukemia: A nationwide multicenter retrospective cohort study

Leukemia Research · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles